Navigation Links
Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College
Date:1/14/2014

VALHALLA, N.Y., Jan. 14, 2014 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the relocation of its corporate headquarters to Valhalla, NY as of January 15, 2014 and expanded lease agreement for additional laboratory space at New York Medical College.

Oligomerix, which is focused on the development of small molecule drugs aimed specifically at inhibiting tau aggregation at the earliest steps of tau self-association into toxic oligomers in neurons, has continued to successfully advance its research, resulting in the need to add staff and expand its office and lab space.

"We're extremely encouraged by the preclinical data we've observed in our lead small molecule program, and are eager to continue our research in this space," stated James Moe, Ph.D., MBA, President and CEO of Oligomerix.  "As New York Medical College is already providing space for in vivo mouse studies for our lead compound, we believe the decision to move and expand Oligomerix's corporate headquarters will benefit the company's logistical needs."

Oligomerix recently announced the appointment of James Hendrix, Ph.D., as the company's Senior Director of Chemistry, and plans to potentially recruit up to five employees in 2014.

ABOUT OLIGOMERIXOligomerix, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. Founded in 2006, the Company is headquartered in Valhalla, NY and is carrying out its in vivo studies at New York Medical College.  The Company is seeking strategic partners to help accelerate these exciting programs.  For more information, visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services. CONTACTS: Oligomerix, Inc.  7 Legion Drive, Valhalla, NY

Tiberend Strategic Advisors, Inc. Jack Pasini 

Andrew Mielach  Chief Commercial Officer 

212-375-2694 917-912-4088

amielach@tiberend.com  jpasini@oligomerix.com 


'/>"/>
SOURCE Oligomerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimers Disease Progression
2. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
3. ImmusanT Relocates Offices to State-of-the-Art Innovation Facility
4. Sysmex America Relocates Corporate Headquarters
5. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
6. Growth Fuels Expansion As PendoTECH Relocates New Jersey Headquarters
7. Optimal Radiology Relocates Headquarters to Nashville
8. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
9. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
10. Survey Shows eContent Critical to Corporate Strategies
11. Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Anaplastic Oligoastrocytoma - Pipeline Review, H2 ... Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma ... of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape. ... when two types of cells in the brain, ... to form a mass. These brain cells are ...
(Date:12/6/2016)... -- Human Vaccines Market: Scope and Methodology ... wise analysis of the human vaccines market. Stakeholders ... products, raw material suppliers, vaccine processing companies, and ... The report provides qualitative and quantitative analysis of ... market dynamics, trends, product overview, and country-level market ...
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on ... user experience. , BOC Global Events & Training Group is a professional event ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “Walking With ... of stories that will inspire the reader to be aware of God's direction in ... of published author, Sanford Smith, retired teacher and active church leader. , ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... NuevaCare, a ... Peninsula region, is proud to announce new city-specific pages as part of its ambitious ... the elderly, they often look, first, for local agencies serving their city. The new ...
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to reduce ... drinking more water or limiting their exposure to the sun, according to a November ... group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ourselves ...
(Date:12/6/2016)... ... 06, 2016 , ... Mount Sinai Health System today announced the creation of ... can confer and order 3D models for their cases. Virtual reality, simulation, and ... times. This resource will be the first of its kind catering to the ...
Breaking Medicine News(10 mins):